ArticleEmerging infectious diseases2020
Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975-2017.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Disseminated Strongyloidiasis Following Chemoradiotherapy for Lung Cancer in a Patient Living in a Non-endemic Area in Japan.Internal medicine (Tokyo, Japan) · 2026Article
- Clinical Insights intoInfection and drug resistance · 2026Article
- Severe ARDS caused byFrontiers in medicine · 2026Article
- Tricky with Heat and Salt: Soil Factors, Thermotaxis, and Potential for Heat-Saline Agar Trapping ofBiology · 2025Article
- AliveWorld journal of gastroenterology · 2025Article
- Strongyloidiasis.Nature reviews. Disease primers · 2024Review
- Antiviral immune response against HTLV-1 invalidates T-SPOT.TBFrontiers in immunology · 2024Article
- The current status of neglected tropical diseases in Japan: A scoping review.PLoS neglected tropical diseases · 2024Article
- Human strongyloidiasis: complexities and pathways forward.Clinical microbiology reviews · 2023Review
- Implementation and Outcomes of an Empiric Ivermectin Strongyloides Treatment Protocol for Patients Receiving High-Dose Corticosteroids for Severe COVID-19.The American journal of tropical medicine and hygiene · 2023Article
- Seropositivity and geographical distribution of Strongyloides stercoralis in Australia: A study of pathology laboratory data from 2012-2016.PLoS neglected tropical diseases · 2021Article
- Case Report: Disseminated Strongyloidiasis in a Patient with COVID-19.The American journal of tropical medicine and hygiene · 2020Article
- Fatal outcome in a patient under immunosuppressant therapy infected with human T-lymphotropic virus type 1 (HTLV-1), cytomegalovirus (CMV) and Strongyloides stercoralis: a case report.BMC infectious diseases · 2020Article
- A Case of Ulcerated Gastric Mass and Anemia due to Strongyloidiasis.Case reports in gastrointestinal medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical characteristics of disseminated strongyloidiasis, the severest form of strongyloidiasis, are not well described. We conducted a retrospective, consecutive chart review of patients with disseminated strongyloidiasis admitted to Okinawa Chubu Hospital in Okinawa, Japan, during January 1975-December 2017. The 70 patients were classified into 3 clinical phenotypes: dissemination (32 patients [45.7%]), occult dissemination with meningitis caused by enteric organisms (12 patients [17.1%]), and occult dissemination with culture-negative suppurative meningitis (26 patients [37.1%]). Associated mortality rates were 56.3%, 16.7%, and 11.5%, respectively, and sepsis occurred in 40.6%, 58.3%, and 11.5% of cases, respectively. Common symptoms included fever (52.9% of patients), headache (32.9%), and altered mental status (24.3%). Patients were treated with thiabendazole (before 2003) or ivermectin (after 2003). Our findings show that disseminated strongyloidiasis has clinical phenotypes in terms of severity and that identification of occult dissemination, a mild form with prominent neurologic manifestations, is lifesaving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.